Weight loss jabs study begins after reports of pancreas issues
A recent initiative has been launched in the UK to investigate reports concerning significant adverse effects linked to widely used weight loss medications, following multiple claims of pancreatic complications. This study, conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) in collaboration with Genomics England, intends to determine if genetic components play a role in adverse reactions to these drugs.Weight loss injections, including well-known brands such as Mounjaro, Ozempic, and Wegovy, have surged in popularity as tools for managing obesity and type 2 diabetes. However, health authorities are now examining reports of both acute and chronic pancreatitis among users.…
